Onyx is now licensed to manufacture commercial API from our UK facility

Knowledge hub

Expert insights from our skilled team

Here at Onyx, our experts are committed to bringing you their latest insights from the API development and manufacturing industry. In our knowledge hub you can find an array of content curated to help you overcome challenges and achieve success.

Insights

Strategies for Control of Potential Mutagenic Impurities (PMIs) in Pharmaceutical Synthesis

During the process of creating pharmaceuticals, one significant concern is […]

Read more
Insights

How limiting N-nitrosamine content helps assure patient safety

N-nitrosamines are organic compounds with the chemical structure R2N-N=O. N-nitrosodimethylamine […]

Read more

International Day for Women and Girls in Science: Denise Bowser

In a recent article, Drug Target Review spoke to Onyx’s […]

Read more
News

Onyx Scientific Targets Stateside Expansion with New Appointment

Leading small molecule CDMO Onyx Scientific is set to expand […]

Read more

Driving sustainability in the pharma industry: Onyx’s perspective (Part 2)

As the demand for sustainably produced medicines rises, to ensure […]

Read more
Insights

Driving sustainability in the pharma industry: Onyx’s perspective (Part 1)

The pharma industry significantly contributes to greenhouse gas emissions, primarily […]

Read more
Insights

Ensuring a Robust Strategy to Navigate the Development of Challenging APIs

Technological advancements such as in silico screening tools and artificial intelligence have […]

Read more
Insights

Striving to Be Sustainable: How Can Pharma Manufacturing Go Green?

The pharma industry is currently striving to embrace sustainable practices […]

Read more
Insights

Mastering drug development with salt screening

Salt screening is a systematic approach used to identify the […]

Read more
Insights

Golden rules for designing a salt screening strategy for insoluble molecules

Developing novel pharmaceutical agents for clinical trials can be challenging for any pharmaceutical innovator. In particular, many drug candidates currently emerging from the discovery stage prese...

Read more
Insights

Whitepaper: Optimizing challenging API salt screening strategy

The landscape presented to those developing novel pharmaceutical agents for […]

Read more
News

Onyx Scientific increases non-GMP capabilities with CMC facility expansion

Sunderland, UK, 28 March – Onyx Scientific, a leading CDMO […]

Read more
News

Onyx bolsters capabilities with commercial API manufacturing license

Onyx Scientific, a small molecule API contract development and manufacturing […]

Read more
Insights

Contract API manufacturing: a shifting landscape

The pharmaceutical industry is evolving and the outsourcing landscape is changing with it. For larger pharmaceutical companies there is a trend towards scaling back their internal capabilities and ...

Read more
Insights

Choosing an API CDMO partner: key considerations

The factors you should consider when identifying and selecting a partner for your next API manufacturing and development project.Selecting the right contract services provider is a vital step in th...

Read more
Insights

Adopting a phase-appropriate solid form journey: what’s the best approach?

Most drug products are administered as solids, with the solid-form properties of active pharmaceutical ingredients (APIs) having a significant impact on a drug’s solubility, dissolution rate, stabi...

Read more
News

Ipca Laboratories announce acquisition of Pisgah Labs Inc.

Ipca Laboratories Ltd. is pleased to announce the acquisition of 100% share capital of Pisgah Labs Inc., a North Carolina Corporation, Old Hendersonville Highway, Pisgah Forest, North Carolina, USA...

Read more
News

Onyx Scientific makes strategic investment in commercial API license

Onyx Scientific has announced that it has made a strategic investment to position the company for a commercial API license. Driven by growing demand for flexible, specialist and small-scale API man...

Read more